IPCA Laboratories Dividend 2026 — ₹6 Per Share, Record Date 7 Aug, Yield Analysis

One-line takeaway: A comfortably-covered, cash-backed dividend that has stepped up sharply in absolute terms — but on a low base. Ipca remains a capital-appreciation stock, not an income stock. The payout ratio is roughly 13%, so the vast majority of earnings is being retained to fund growth.

At its board meeting on 29 May 2026 (11:30 a.m. to 1:45 p.m.), the Board of Directors of Ipca Laboratories recommended a final dividend of ₹6 per equity share of ₹1 each (600%) for the financial year ended 31 March 2026. The Board fixed Friday, 7 August 2026 as the record date for member entitlement.

The recommendation was placed “subject to the approval of shareholders at the ensuing Annual General Meeting.” Per exchange disclosures, Ipca held its 76th AGM on 13 August 2026 and shareholders passed all resolutions, including the dividend. The payout is therefore confirmed for eligible shareholders. This is a single final dividend; the company did not declare an interim dividend for FY26.

Editorial note: The company did not publish a separate ex-date or a firm payment date in the board outcome. The ex-date shown is the standard T+1 convention (same as record date) and must be verified against the NSE/BSE corporate-action circular before publication. The payment date reflects only the statutory outer limit, not a company-disclosed date.

The headline number — 600% — is the dividend expressed as a percentage of the ₹1 face value. It is not the return an investor earns. Because Ipca trades at roughly ₹1,886, the actual cash yield is a fraction of a percent.

Yield reality check: The yield here is low for a healthy reason, not a distressed one. It is driven by a high, appreciating share price against a deliberately modest payout — the opposite of the classic “high yield from a collapsing price” trap. Ipca’s yield sits below the pharma sector average of roughly 0.7–0.8%.

The real story: The ₹6 final is the single largest dividend Ipca has declared in recent history — roughly 3× the ₹2 tranche paid a year earlier. Yet because earnings have grown even faster, the payout ratio has barely moved (still ~13%). The step-up signals management comfort with cash generation, not a shift to a high-distribution policy.

Base-effect flattery — the headline overstates the trend

The reported +54.7% jump in consolidated profit (and +74% at standalone level) looks spectacular, but it is heavily inflated by a depressed prior-year base. FY25 absorbed roughly ₹205 Cr of exceptional charges (impairments of overseas subsidiary/associate exposure and an EU fine settlement), versus only ₹86.43 Cr of exceptionals in FY26. Stripping those out, the cleaner before-exceptional profit growth is about +29% consolidated. Revenue grew a more pedestrian ~8%. The genuine operating story is EBITDA margin expansion (roughly 18% EBITDA growth on 8% revenue growth), not a doubling of the business.

Reported profit is an accounting opinion; the dividend is paid in cash. On this test Ipca screens well. Standalone operating cash flow of ₹1,378.12 Cr comfortably exceeds standalone profit of ₹1,132.52 Cr — an OCF-to-PAT ratio of ~1.22x, indicating high-quality, cash-backed earnings rather than paper profit.

How the dividend is funded: Entirely from current-year free cash flow. There is no evidence the payout relies on drawing down reserves, selling assets, or raising borrowings. Even after ~₹650–665 Cr of capex, the business threw off enough surplus cash to fund the dividend several times over.

Net cash position — not net debt

Standalone borrowings total ₹235.16 Cr against ₹711.21 Cr of liquid assets — a net cash position of ~₹476 Cr. On a consolidated basis, borrowings of ₹703.94 Cr are still exceeded by liquid assets of ₹1,198.01 Cr, a net cash position of ~₹494 Cr. Consolidated net worth attributable to owners stands at ₹8,063.81 Cr. The dividend is not being paid by a leveraged balance sheet.

Classification: Sustainable. All four coverage tests pass with wide margins, the balance sheet is in net cash, and the payout ratio (~13%) leaves ample buffer. The principal caveat is not affordability but consistency of policy — Ipca’s dividend has historically been variable, so a ₹6 payout in FY26 does not guarantee a ₹6 (or higher) payout in FY27. Sustainability of the amount is high; predictability of the trajectory is only moderate.

Peer dividend, yield and payout figures are external, drawn from public sources for FY26 and must be independently re-verified; blank cells are left blank rather than estimated. The takeaway is directional: Ipca is among the lowest-yielding names in the large-cap pharma set, with a payout ratio well below Sun Pharma’s ~33%. This reflects Ipca’s reinvestment-heavy, capital-appreciation profile rather than any inability to pay.

A little under half the dividend flows to the promoter group (the Godha family). Because promoter holding is under 50%, the majority of the cash reward — roughly ₹84 Cr — goes to non-promoter shareholders, led by domestic institutions. There is no pledged-promoter distortion; the payout is a straightforward pro-rata distribution.

Since the abolition of the Dividend Distribution Tax (FY2020-21 onwards), dividends are taxed in the hands of the shareholder. Key rules:

• Dividend is added to “Income from Other Sources” and taxed at the investor’s applicable slab rate.

• The company deducts TDS at 10% if total dividend paid to a resident shareholder exceeds ₹10,000 in a financial year (20% if PAN is not furnished).

• Non-resident (NRI) shareholders face 20% TDS or the applicable DTAA rate.

Worked example — 1,000 shares at 30% slab

Gross dividend: 1,000 × ₹6 = ₹6,000

TDS at source: ₹0 (below the ₹10,000 threshold, so no TDS is deducted here)

Tax at 30% slab (plus applicable cess): ~₹1,800 + cess, payable via the investor’s return

Net in-hand after tax: ~₹4,200 (approx., before cess)

Effective post-tax yield at a ₹1,886 price: roughly 0.22%. A shareholder holding enough stock for dividends above ₹10,000 would see 10% TDS withheld upfront and adjust the balance in their return.

Ipca Laboratories’ FY26 final dividend of ₹6 per share is genuine, cash-backed and comfortably affordable — covered 7.4 times by earnings, 4.7 times by standalone free cash flow, and sitting on a net-cash balance sheet. In absolute terms it is a landmark payout, roughly triple the prior year’s tranche.

But two realities temper the headline. First, the “600%” is a face-value optical effect — the real yield is about 0.32%, below the pharma sector average. Second, the eye-popping ~55% profit jump is substantially a base effect: strip out the prior year’s heavy impairment and fine charges, and underlying growth is a healthy-but-normal ~29%. Ipca remains, unambiguously, a growth and capital-appreciation stock that pays a modest, well-covered dividend — not an income play. The positives (coverage, cash, margin expansion) and the watch-items (yield, policy consistency, exceptional-item noise, valuation) are laid out above for readers to weigh themselves.